search
Back to results

A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells)

Primary Purpose

Rabies Vaccine Adverse Reaction, Safety and Efficacy

Status
Recruiting
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 5-dose program
Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 4-dose program
Freeze-dried human rabies vaccine (Vero cells) Chengda - 5-dose program
Freeze-dried human rabies vaccine (Vero cells) Chengda - 4-dose program
Sponsored by
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Rabies Vaccine Adverse Reaction

Eligibility Criteria

10 Years - 60 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age 10-60 on the day of enrollment, able to provide legal identification
  • Subjects and/or their guardians voluntarily agree to participate in the study and sign an adult informed consent form or a minor's informed consent form
  • Subjects and/or their legal guardians have the ability to understand (non-illiterate) research procedures and participate in all planned follow-ups
  • On the day of enrollment, the axillary body temperature of people aged 14 and under was <37.5℃, and the axillary body temperature of people over 14 years of age was <37.3℃
  • Female subjects of childbearing age were not breast-feeding at the time of enrollment, were not pregnant (the urine pregnancy test was negative before vaccination (on the day)), had no pregnancy plan within 2 months after enrollment, and agreed to take effective measures within 2 months after enrolling in the study Contraceptive measures

Exclusion Criteria:

  • Have a history of rabies vaccination or use of rabies virus passive immunization preparations
  • A history of bites by mammals (such as dogs, cats, etc.) within 1 year before the first dose of vaccination (wound skin damage)
  • Previous vaccination has a history of severe allergies to any vaccine component that requires medical intervention: such as anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis, severe urticaria, etc.
  • Within 3 days before vaccination, acute febrile disease (body temperature under armpit>38.5℃) or in the acute onset of chronic disease, or taking antipyretic, analgesic, and anti-allergic drugs
  • Have received blood/blood-related products or immunoglobulins within 3 months before the first dose of vaccination; or plan to use such products within 1 month after the last dose of vaccination
  • Get any vaccine within 14 days before the first dose of vaccination
  • Any condition (such as splenectomy) caused asplenia or functional asplenia
  • Has been diagnosed with congenital or acquired immunodeficiency (HIV), or received immunosuppressive therapy within 3 months
  • Severe congenital malformations or autoimmune (hereditary) diseases, serious chronic diseases (including but not limited to: heart disease, kidney disease, diabetes with comorbidities, allergic constitution, Guillain-Barre syndrome, etc.), evaluated by the investigator that it may affect research evaluation
  • People with a history or family history of convulsions, epilepsy, encephalopathy, and psychosis (including but not limited to: congenital brain hypoplasia, brain trauma, brain tumor, cerebral hemorrhage, cerebral obstruction, brain nerve tissue damage caused by infection, chemical drug poisoning, etc.)
  • There are contraindications for intramuscular injection (diagnosed as any coagulation disorder or receiving anticoagulant treatment)
  • Are participating in other research or unregistered products (drugs, vaccines or devices, etc.) clinical research, or plan to participate in other clinical research before the end of this clinical research
  • The researcher believes that the subject has any conditions that may interfere with the evaluation of the research purpose

Sites / Locations

  • Hunan Provincial Center for Disease Control and PreventionRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Active Comparator

Active Comparator

Arm Label

Investigational Vaccine - 5-dose program

Investigational Vaccine - 4-dose program

Control vaccine - 5-dose program

Control vaccine - 4-dose program

Arm Description

Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.

Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.

Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.

Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.

Outcomes

Primary Outcome Measures

Antibody positive conversion rate - Immunogenicity endpoint
Antibody positive conversion rate of the test group and the control group of the pre-immune antibody-negative population
Geometric mean concentration - Immunogenicity endpoint
Geometric mean concentration of the test group and the control group of the pre-immune antibody-negative population
Incidence of Adverse Events [Safety and Tolerability]
Incidence of Adverse Events
Incidence of Serious Adverse Events [Safety and Tolerability]
Incidence of Serious Adverse Events

Secondary Outcome Measures

Antibody positive conversion rate - Immunogenicity endpoint
Antibody positive conversion rate
Geometric mean concentration - Immunogenicity endpoint
Geometric mean concentration

Full Information

First Posted
April 12, 2021
Last Updated
June 13, 2023
Sponsor
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04852068
Brief Title
A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells)
Official Title
A Randomized, Blinded, and Similar Vaccine-controlled Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of the 5-dose Program and 4-dose (2-1-1) Program of Freeze-dried Human Rabies Vaccine (Vero Cells)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 10, 2021 (Actual)
Primary Completion Date
September 30, 2023 (Anticipated)
Study Completion Date
October 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This clinical trial is carried out in two phases. The first phase adopts an open design, and the second phase adopts a randomized, blinded, and similar vaccine-controlled non-inferiority trial design. The first stage: According to the order of two age groups of 18-60 years old and 10-17 years old, 40 cases were enrolled in each age group (20 persons for the 5-dose program and 20 for the 4-dose program). Subjects in the 5-dose group received 1 dose of test vaccine on 0, 3, 7, 14, and 28 days each. Subjects in the 4-dose group received 1 dose each on both arms on day 0, and 1 dose on day 7 and day 21 each. All subjects in the first stage were only observed for safety and were followed up to 6 months after the entire course of vaccination. The second stage: the total number of enrolled 2400 cases, 10-60 years old, the 4-dose program group and the 5-dose program group of the test vaccine, the 4-dose program group and the 5-dose program group of the control vaccine according to the random ratio 1:1:1:1. Among the total number of participants, 1680 cases (420 cases per group) were simultaneously observed for immunogenicity and safety, and the remaining 720 subjects (180 cases per group) only underwent safety observation. 800 subjects (200 cases in each group) received 6-month immune persistence observation after full vaccination, and 400 subjects in the test vaccine group received 12 months immune persistence observation after full vaccination. In the second stage, 1680 subjects were collected before the immunization, 7 days after the first dose, 14 days after the first dose, and 14 days after the full vaccination to test rabies virus antibodies to evaluate the immunogenicity of the test vaccine. 800 subjects were in the whole process Immune persistent blood sampling was performed 6 months after vaccination, and subjects in the test vaccine group were further subjected to immune persistent blood sampling 12 months after the full course of vaccination to evaluate immune durability. Collect all AEs within 30 minutes after each dose, AEs from 0-7 days, all non-collective AEs from the first dose to 30 days after the full course of vaccination, and all serious AEs from the first dose to 6 months after the full course of vaccination Adverse events.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rabies Vaccine Adverse Reaction, Safety and Efficacy

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Similar vaccine control
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
2480 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Investigational Vaccine - 5-dose program
Arm Type
Experimental
Arm Description
Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
Arm Title
Investigational Vaccine - 4-dose program
Arm Type
Experimental
Arm Description
Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
Arm Title
Control vaccine - 5-dose program
Arm Type
Active Comparator
Arm Description
Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.
Arm Title
Control vaccine - 4-dose program
Arm Type
Active Comparator
Arm Description
Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.
Intervention Type
Biological
Intervention Name(s)
Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 5-dose program
Intervention Description
Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
Intervention Type
Biological
Intervention Name(s)
Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 4-dose program
Intervention Description
Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
Intervention Type
Biological
Intervention Name(s)
Freeze-dried human rabies vaccine (Vero cells) Chengda - 5-dose program
Intervention Description
Inoculate 1 dose of control vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
Intervention Type
Biological
Intervention Name(s)
Freeze-dried human rabies vaccine (Vero cells) Chengda - 4-dose program
Intervention Description
Inoculate 1 dose of control vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
Primary Outcome Measure Information:
Title
Antibody positive conversion rate - Immunogenicity endpoint
Description
Antibody positive conversion rate of the test group and the control group of the pre-immune antibody-negative population
Time Frame
14 days after the first dose of vaccination
Title
Geometric mean concentration - Immunogenicity endpoint
Description
Geometric mean concentration of the test group and the control group of the pre-immune antibody-negative population
Time Frame
14 days after the first dose of vaccination
Title
Incidence of Adverse Events [Safety and Tolerability]
Description
Incidence of Adverse Events
Time Frame
within 30 minutes after each dose of vaccination; the first dose of vaccination to 30 days after the full course of vaccination
Title
Incidence of Serious Adverse Events [Safety and Tolerability]
Description
Incidence of Serious Adverse Events
Time Frame
The first dose of vaccination to 6 months after the full course of vaccination
Secondary Outcome Measure Information:
Title
Antibody positive conversion rate - Immunogenicity endpoint
Description
Antibody positive conversion rate
Time Frame
7 days after the first dose of vaccination; 14 days, 6 months, 12 months after the full vaccination
Title
Geometric mean concentration - Immunogenicity endpoint
Description
Geometric mean concentration
Time Frame
7 days after the first dose of vaccination; 14 days, 6 months, 12 months after the full vaccination

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 10-60 on the day of enrollment, able to provide legal identification Subjects and/or their guardians voluntarily agree to participate in the study and sign an adult informed consent form or a minor's informed consent form Subjects and/or their legal guardians have the ability to understand (non-illiterate) research procedures and participate in all planned follow-ups On the day of enrollment, the axillary body temperature of people aged 14 and under was <37.5℃, and the axillary body temperature of people over 14 years of age was <37.3℃ Female subjects of childbearing age were not breast-feeding at the time of enrollment, were not pregnant (the urine pregnancy test was negative before vaccination (on the day)), had no pregnancy plan within 2 months after enrollment, and agreed to take effective measures within 2 months after enrolling in the study Contraceptive measures Exclusion Criteria: Have a history of rabies vaccination or use of rabies virus passive immunization preparations A history of bites by mammals (such as dogs, cats, etc.) within 1 year before the first dose of vaccination (wound skin damage) Previous vaccination has a history of severe allergies to any vaccine component that requires medical intervention: such as anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis, severe urticaria, etc. Within 3 days before vaccination, acute febrile disease (body temperature under armpit>38.5℃) or in the acute onset of chronic disease, or taking antipyretic, analgesic, and anti-allergic drugs Have received blood/blood-related products or immunoglobulins within 3 months before the first dose of vaccination; or plan to use such products within 1 month after the last dose of vaccination Get any vaccine within 14 days before the first dose of vaccination Any condition (such as splenectomy) caused asplenia or functional asplenia Has been diagnosed with congenital or acquired immunodeficiency (HIV), or received immunosuppressive therapy within 3 months Severe congenital malformations or autoimmune (hereditary) diseases, serious chronic diseases (including but not limited to: heart disease, kidney disease, diabetes with comorbidities, allergic constitution, Guillain-Barre syndrome, etc.), evaluated by the investigator that it may affect research evaluation People with a history or family history of convulsions, epilepsy, encephalopathy, and psychosis (including but not limited to: congenital brain hypoplasia, brain trauma, brain tumor, cerebral hemorrhage, cerebral obstruction, brain nerve tissue damage caused by infection, chemical drug poisoning, etc.) There are contraindications for intramuscular injection (diagnosed as any coagulation disorder or receiving anticoagulant treatment) Are participating in other research or unregistered products (drugs, vaccines or devices, etc.) clinical research, or plan to participate in other clinical research before the end of this clinical research The researcher believes that the subject has any conditions that may interfere with the evaluation of the research purpose
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fangjun Li, Bachelor
Phone
13574109585
Email
646022285@qq.com
Facility Information:
Facility Name
Hunan Provincial Center for Disease Control and Prevention
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410005
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fangjun Li, Bachelor
Phone
13574109585
Email
646022285@qq.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells)

We'll reach out to this number within 24 hrs